...
首页> 外文期刊>Biomedicine & pharmacotherapy =: Biomedecine & pharmacotherapie >Can Src protein tyrosine kinase inhibitors be combined with opioid analgesics? Src and opioid-induced tolerance, hyperalgesia and addiction
【24h】

Can Src protein tyrosine kinase inhibitors be combined with opioid analgesics? Src and opioid-induced tolerance, hyperalgesia and addiction

机译:可以将SRC蛋白酪氨酸激酶抑制剂与阿片类药物镇痛药结合吗? SRC和阿片类药物诱导的耐受性,痛觉过敏和成瘾

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The clinical application of opioids may be accompanied by a series of adverse consequences, such as opioid tolerance, opioid-induced hyperalgesia, opioid dependence or addiction. In view of this issue, clinicians are faced with the dilemma of treating various types of pain with or without opioids. In this review, we discuss that Src protein tyrosine kinase plays an important role in these adverse consequences, and Src inhibitors can solve these problems well. Therefore, Src inhibitors have the potential to be used in combination with opioids to achieve synergy. How to combine them together to maximize the analgesic effect while avoiding unnecessary trouble provides a topic for follow-up research.
机译:阿片类药物的临床应用可能伴随着一系列不良后果,如阿片耐受、阿片诱导的痛觉过敏、阿片依赖或成瘾。鉴于这一问题,临床医生面临着使用或不使用阿片类药物治疗各种类型疼痛的困境。在这篇综述中,我们讨论了Src蛋白酪氨酸激酶在这些不良后果中起着重要作用,Src抑制剂可以很好地解决这些问题。因此,Src抑制剂有可能与阿片类药物联合使用以实现协同作用。如何将它们结合起来,在避免不必要的麻烦的同时最大限度地发挥镇痛效果,为后续研究提供了一个课题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号